Drug addiction is a complex, chronic relapsing illness characterized by compulsive drug use. It is a serious public health issue that affects the individual, family, and communities at large. It is one of the most difficult forms of addiction to overcome and is associated with a wide variety of short-term and long-term physical and mental health consequences. Drug addiction is a form of substance-use disorder which occurs when a person develops an intense craving and compulsion to take drugs. It is a progressive illness which makes it difficult to stop using drugs, even when the individual knows the negative consequences of their drug use. Drug addiction also changes the structure and functioning of the brain affecting psychology and behaviour. It is a complex chronic illness, with social, genetic, and environmental determinants. Once an individual becomes addicted to drugs, their body starts to develop a tolerance to the drug, meaning they need higher amounts over time to produce the same effect. The individual may also experience severe physical and psychological withdrawal symptoms, when the drug is stopped abruptly, making it hard to maintain abstinence from drugs. Treatment for drug addiction is an essential part of recovery. Medications such as methadone or buprenorphine, as well as comprehensive behavioral therapy, have been shown to be effective in treating drug addiction. Treatment should focus on the individual, not just their drug abuse. Treatment should be tailored to the individual needs, addressing the motivations for drug use and addressing the psychological and social issues associated with substance use. Life-long recovery from drug addiction is possible, but is dependent on the individual's commitment to making long-term changes to their lifestyle and behavior.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States